None
Quote | Oncternal Therapeutics Inc. (NYSE:ONCT)
Last: | $ |
---|---|
Change Percent: | 1.28% |
Open: | $3.87 |
Close: | $3.95 |
High: | $3.95 |
Low: | $3.87 |
Volume: | 7,823 |
Last Trade Date Time: | 02/12/2020 04:42:01 pm |
News | Oncternal Therapeutics Inc. (NYSE:ONCT)
2024-05-09 18:34:06 ET Oncternal Therapeutics, Inc. (ONCT) Q1 2024 Earnings Call Transcript May 9, 2024 05:00 PM ET Company Participants Richard Vincent - CFO Dr. James Breitmeyer - President and CEO Dr. Salim Yazji - Chief Medical Officer Conference Call P...
2024-05-09 17:01:05 ET More on Oncternal Therapeutics Oncternal Therapeutics, Inc. (ONCT) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Oncternal Therapeutics Historical earnings data for Oncternal Therapeutics Financial information ...
Message Board Posts | Oncternal Therapeutics Inc. (NYSE:ONCT)
Subject | By | Source | When |
---|---|---|---|
I think that $ONCT has huge potential, but | Tartiaboy | investorshub | 03/31/2023 5:25:45 PM |
znewcar1: $ONCT 24% v528K c.8778 f58,711M H.878 ML.5951 | znewcar1 | investorshangout | 03/23/2023 9:00:25 PM |
Tartia or Decaf, Time to buy more, or sell?tia | spiderman3600 | investorshub | 03/10/2023 4:33:35 PM |
https://stocktwits.com/Stockholm111/message/509113960 | spiderman3600 | investorshub | 01/30/2023 9:48:44 PM |
I am anxiously waiting for $ONCT to initiate | Tartiaboy | investorshub | 01/27/2023 5:32:44 PM |
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NYSE Market:
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2024 financial results after the U.S. financial markets clo...
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-5...